1. Proportion of total R&D expenditure by function in 2005
APRIL 2007
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your use of these materials is subject to the terms and conditions hereof. Please read the disclaimer carefully before using these materials.

2. Proportion of total R&D expenditure by function in 2005
Chapter 3
R&D Functions
Figure 3.1
Proportion of total R&D expenditure by function in 2005
Key message
In 2005, the Clinical and Discovery functions together accounted for close to 60% of total R&D expenditure for 20 pharmaceutical companies.
Methodology
Presented is the proportion of R&D expenditure in 2005 allocated to different R&D functions calculated as an aggregate of the data provided by 20 companies (10 Major and 10 Mid and Other). The total R&D expenditure represented in the figure is US$ billion.
Key Definitions
Discovery function: All activities conducted to identify targets, and active substances which would modify target activity for therapeutic use, to the stage where an active substance can be safely and practically tested in humans. This includes all activities from idea generation, basic research, synthesis and screening (including biological and pharmacological screening), ADME studies (absorption, distribution, metabolism and excretion) and any pre-clinical development work (including process and formulation research) that will be associated with producing an active substance to be tested in humans for the first time.
Non-clinical safety evaluation function: All in vitro and in vivo (animals only) toxicological, safety and associated kinetic tests.
CMC function: Chemistry, Manufacturing and Controls. All activities conducted to optimise, scale-up and validate the processes and technologies for transfer to manufacture and all QA, QC and CMC support activities (e.g. CMC project management including CMC contribution to project teams). This includes all Drug Substance R&D i.e. process research and process development, all Drug Product R&D i.e. formulation development and process development, clinical supplies. This includes all analytical work for Drug Substance R&D and Drug Product R&D.
See also definitions for Clinical and Regulatory functions in Figure 3.2.
CMR International Performance Metrics Programme / Source
Industry R&D Investment Programme
The proportion of total R&D expenditure by function presented in this figure is based on data from 20 companies (10 Major and 10 Mid and Other)
Total R&D expenditure = US$ 33.79bn
Major companies are defined as those spending ≥US$ 1.8 billion in 2005 on ethical pharmaceutical R&D.
Mid and Other companies are defined as those spending <US$ 1.8 billion in 2005 on ethical pharmaceutical R&D.
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS

3. Terms of Use and Disclaimer
The materials contained in these slides may be used for your own use in presenting at conferences and meetings or for inclusion in reports provided that you acknowledge the source of the materials and include the following statement: “2008 © Thomson Reuters. Some of the materials and/or data in this [report, presentation, paper etc] are reproduced under a license from Thomson Reuters. You may not copy or re-distribute these materials in whole or in part without the written consent of Thomson Reuters”.
Charts, graphs, and illustrations contained in these slides may not be decompiled, reverse engineered, or disassembled.
The copyright and other intellectual property rights in these slides is owned by Thomson Reuters or its licensors. Except for the license set out in these Terms of Use, Thomson Reuters neither assigns any rights nor grants any licenses or rights in respect of these slides to you and any use of these slides other than in accordance with these Terms of Use is subject to Thomson Reuters’ prior written consent. For additional permissions, please contact: [contact ]
THOMSON REUTERS MAKES NO WARRANTY OR REPRESENTATION AS TO THE ACCURACY, COMPLETENESS OR CORRECTNESS OF ANY MATERIALS CONTAINED WITHIN THESE SLIDES OR THAT ALL ERRORS IN THE SLIDES OR THE MATERIALS CONTAINED WITHIN THESE SLIDES WILL BE CORRECTED.
THOMSON REUTERS IS AN INFORMATION PROVIDER AND DOES NOT PROVIDE LEGAL, FINANCIAL OR OTHER PROFESSIONAL ADVICE. THE MATERIALS CONTAINED IN THESE SLIDES ARE FOR GENERAL INFORMATION PURPOSES ONLY, ARE NOT INTENDED TO CONSTITUTE LEGAL OR OTHER PROFESSIONAL ADVICE, AND SHOULD NOT BE RELIED ON OR TREATED AS A SUBSTITUTE FOR SPECIFIC ADVICE RELEVANT TO PARTICULAR CIRCUMSTANCES. THOMSON REUTERS SHALL NOT BE LIABLE FOR ANY LOSS THAT MAY ARISE FROM ANY RELIANCE BY YOU, YOUR EMPLOYER OR CLIENT, OR ANY OTHER THIRD PARTY, ON THE MATERIALS CONTAINED IN THESE SLIDES.
THOMSON REUTERS WILL NOT BE LIABLE IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE FOR ANY INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL LOSS OR DAMAGE ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OF USE OR YOUR USE OF THE SLIDES, HOWEVER SUCH INDIRECT LOSS OR DAMAGE MAY ARISE.
You shall not assign, sub-licence or delegate any of your rights or obligations under these Terms of Use without the prior written consent of Thomson Reuters; any assignment, sub-licensing or delegation in breach of these Terms of Use shall be null and void. If any provision of these Terms of Use are determined to be illegal or unenforceable by any court of competent jurisdiction it shall be deemed to have been deleted without affecting the remaining provisions. These Terms of Use will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania. You hereby irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Philadelphia, PA, USA.